Nanotechnology based approach for hepatocellular carcinoma targeting
Hepatocellular carcinoma (HCC) is the primary liver cancer that has shown a high incidence
and mortality rate worldwide among several types of cancers. A large variety of …
and mortality rate worldwide among several types of cancers. A large variety of …
Nanomedicine as a putative approach for active targeting of hepatocellular carcinoma
MH Elnaggar, AI Abushouk, AHE Hassan… - Seminars in cancer …, 2021 - Elsevier
The effectiveness of chemotherapy in hepatocellular carcinoma (HCC) is restricted by
chemo-resistance and systemic side effects. To improve the efficacy and safety of …
chemo-resistance and systemic side effects. To improve the efficacy and safety of …
[HTML][HTML] Nanoparticle drug delivery systems in hepatocellular carcinoma: a focus on targeting strategies and therapeutic applications
Hepatocellular carcinoma (HCC) is recognized as a global health issue accounting for
millions of deaths every year. Surgery, liver ablation, and embolization therapy are amongst …
millions of deaths every year. Surgery, liver ablation, and embolization therapy are amongst …
Current status and future directions of hepatocellular carcinoma-targeted nanoparticles and nanomedicine
Introduction Hepatocellular carcinoma (HCC) is a major health problem worldwide.
Conventional therapies covering either chemotherapy or combination therapy still have sub …
Conventional therapies covering either chemotherapy or combination therapy still have sub …
Nanocarrier-based tumor-targeting drug delivery systems for hepatocellular carcinoma treatments: Enhanced therapeutic efficacy and reduced drug toxicity
T Tian, J Ruan, J Zhang, CX Zhao… - Journal of biomedical …, 2022 - ingentaconnect.com
Hepatocellular carcinoma (HCC), due to the lack of efficient diagnostic methods and short of
available treatments, becomes the third main cause of cancer deaths. Novel treatments for …
available treatments, becomes the third main cause of cancer deaths. Novel treatments for …
Recent advances in drug delivery nanocarriers for targeting hepatocellular carcinoma
S Wang, Q Lv, X Li - Journal of Nanomaterials, 2022 - Wiley Online Library
Hepatocellular carcinoma (HCC) is among the primary drivers of cancer‐related death
globally, owing to the ineffectiveness of treatments in intermediate and terminal stages—an …
globally, owing to the ineffectiveness of treatments in intermediate and terminal stages—an …
[HTML][HTML] Precision targeting in hepatocellular carcinoma: Exploring ligand-receptor mediated nanotherapy
XQ Zhou, YP Li, SS Dang - World Journal of Hepatology, 2024 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and poses a
major challenge to global health due to its high morbidity and mortality. Conventional …
major challenge to global health due to its high morbidity and mortality. Conventional …
Drug delivery system targeting advanced hepatocellular carcinoma: Current and future
Hepatocellular carcinoma (HCC) has a fairly high morbidity and is notoriously difficult to treat
due to long latent period before detection, multidrug resistance and severe drug-related …
due to long latent period before detection, multidrug resistance and severe drug-related …
Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma
M Li, W Zhang, B Wang, Y Gao, Z Song… - International Journal of …, 2016 - Taylor & Francis
Hepatocellular carcinoma (HCC) is the most common primary liver cancer with high
morbidity and mortality worldwide. Chemotherapy is recommended to patients with …
morbidity and mortality worldwide. Chemotherapy is recommended to patients with …
Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances
Liver cancer is considered one of the deadliest diseases with one of the highest disease
burdens worldwide. Among the different types of liver cancer, hepatocellular carcinoma is …
burdens worldwide. Among the different types of liver cancer, hepatocellular carcinoma is …